Oncopeptides: 157% subscription rate - Redeye
Bildkälla: Stockfoto

Oncopeptides: 157% subscription rate - Redeye

Redeye is not surprised by the high subscription rate, considering the share has traded above the strike price. The amount received should cover the company until reaching a positive cash flow.

Redeye is not surprised by the high subscription rate, considering the share has traded above the strike price. The amount received should cover the company until reaching a positive cash flow.
Börsvärldens nyhetsbrev